MakeMyTrip Ltd vs Tilray Brands Inc — how do they compare? MakeMyTrip Ltd trades at $44.57 (market cap $4.09B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: MakeMyTrip Ltd is far larger — about 7.7× Tilray Brands Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Tilray Brands Inc for 31 Days on average.
| MMYT | TLRY | |
|---|---|---|
Market Cap | $4.09B | $530.54M |
Volume | 1,828,010 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $21.00 |
52-Week Low | $36.30 | $3.57 |
Typical Hold Time | 12 Days | 31 Days |
Enterprise Value | $4.75B | $684.46M |
Signals from Pluang's Aura AI — not financial advice
MMYT trades at $44.33, up 2.12% today, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, though net income margin remains thin at 3.23%. Analyst consensus is strongly bullish with a $77.00 price target, but institutional selling and a projected decline in 2026 cash flow pose concerns.
The stock presents a high-risk, high-reward opportunity. Strong analyst support and a potential Indian listing offer upside, but bearish technicals, earnings volatility, and rising debt-to-asset ratios in 2026 highlight significant risks. Investors should weigh the optimistic price targets against fundamental pressures and market sentiment.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →